Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma | videos

<< Go Back

$An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.$

Examining Ongoing Studies of Mosunetuzumab for R/R Follicular Lymphoma and Addressing Accessibility

January 19th 2023

An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting.

An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.

Mosunetuzumab Appears to Reduce Unmet Needs Associated With CAR T-Cell Therapy for R/R Follicular Lymphoma

January 17th 2023

An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access.

$An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.$

Approval of Mosunetuzumab Becomes ‘Critically Important’ First-Line Treatment Option in R/R Follicular Lymphoma, Expert Says

January 15th 2023

An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777